This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With ongoing demand for specialty drugs, biologics, and generics, privateequity sees long-term value in platforms that can scale and innovate within FDA-compliant environments. Medical Equipment and Supplies Manufacturing From surgical instruments to diagnostic devices, this sector is central to modern healthcare delivery.
2025 Dental Transactions Update As of June 2025, our research shows approximately 130 privateequity backed DSOs operating across the dental services landscape – more than in any other healthcare vertical. DSO Creation Privateequity investment in dental practices began in the 1990’s when the first DSOs sought outside investors.
In the pursuit of attractive equity returns, privateequity firms have developed numerous innovative strategies beyond typical leveraged buyouts and take-private transactions. As it happens, this is an industry that has experienced a significant amount of privateequity-backed roll-up activity.
When you hear the words “healthcare privateequity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? In most of the world, healthcare is either government-run or a mixed public/private sector. Are there many private healthcare companies for PE firms to acquire?
Armed with anywhere between $2 trillion and $4 trillion of “dry powder”—with about half of that targeted to healthcare—privateequity firms have a lot of capital to put to work. ENT and allergy is relatively new to privateequity investment, with approximately ten major platforms currently operating.
Compared to other medical fields like dentistry and dermatology, privateequity involvement in orthopedic practices has been relatively small. Despite the recent rash of M&A deals, the orthopedic business, like other medical fields, remains highly fragmented.
By Dom Walbanke on Growth Business - Your gateway to entrepreneurial success UPDATED: The UK has the most developed web of angel investor networks in Europe with 15,000 angel investors dotted around the country, according to the UK Business Angels Association (UKBAA). They’ve been generous with their cash, too.
For top privateequity firms, there’s a lot to like about SaaS. Top Software PrivateEquity Firms Here is a select list of the most active PE investors in the SaaS and software industry over the past year (data taken from the SEG 2024 Annual SaaS Report ). The firm employs 93 professionals.
This article focuses on how medical practices are valued by privateequity-backed groups, and to an extent, health systems and other strategic acquirers. Physician practices are almost always valued on a multiple of EBITDA basis in transactions with privateequity groups or similar buyers.
3 spot on The Deal’s privateequity league table for law firms. The combination with Waller gave Holland & Knight increased capabilities in healthcare, well as in privateequity, financial services, real estate and litigation. As of March, the merged entity had nearly 2,000 attorneys in 34 offices in the U.S.
Direct-to-consumer businesses, darlings of the investor community in 2021, saw their techlike valuations plummet. But some subsectors, such as beauty, fragrance, residential services and medical spas, remained active as risk-off investors shifted deal activity toward categories they view as less discretionary, according to Leonhardt.
Excolere Equity Partners is a leading middle market privateequity firm that leverages its deep sector experience and strategic and operational expertise to accelerate the growth and enhance the impact of companies in the Education and Human Capital sector. ISP Schools is a portfolio company of OMERS PrivateEquity.
Despite investment in the first half of 2023 dropping to £4.6bn from 2022’s £10.8bn as a result of rising interest rates, high inflation, a decrease in valuations and geopolitical tensions globally, UK fintechs are still attracting more VC investment than all other EMEA fintechs combined, with a significant percentage coming from US investors.
Update on PrivateEquity and Insurance Brokerages In our ,, previous article , we reported that the COVID-19 pandemic had not diminished the pace of mergers and acquisitions transactions we are seeing in the insurance agency and brokerage sector. The number of transactions we are working on has not abated.
On April 23 a group led by privateequity firm TPG agreed to acquire OneOncology, the nation’s largest independent community oncology network, in a deal valued at $2.1 While the biggest recent deal, OneOncology is hardly the first oncology platform to be sold to a privateequity group. US Oncology Network.
It is a form of equity funding that precedes venture capital and privateequity. It is the third biggest investor type into UK start-ups, after crowdfunding, venture capital & privateequity, according to research group Beauhurst. How do I find an angel investor?
Based on the large number of medical practices acquired over the past decade, you may think selling your practice is a routine process. The FOCUS healthcare team offers a process tailored to physician groups in privateequity transactions. If you don’t think you can work together, it is best not to go any further.
Serving a variety of end markets, including aerospace & defense, electronics and industrials, National offers especially deep experience in the medical end market across various implantable devices, including pacemakers, neuromodulation devices, defibrillators, batteries and capacitors. National”). appeared first on FOCUS.
As we project toward 2025, this sector is poised to sustain its robust performance, driven by substantial investor interest and the opportunities presented by a highly fragmented market. In 2025, investors are expected to focus increasingly on companies that enhance operational efficiencies within the education sector.
Summary Privateequity’s investments in ophthalmology are entering a new, more mature lifecycle phase. We also expect many platform recapitalizations once privateequity groups and lenders become comfortable with the interest rate environment. Platform Creation” transactions are very rare. A third group (e.g.,
Periculum Capital Company, LLC is pleased to announce it has advised Micro-Dyn Medical Systems, Inc., based privateequityinvestor that specializes in acquiring software businesses in partnership with top mid-career executives. a leading health care software company, in its acquisition by The Brydon Group.
Complex and novel transaction structures for the sector also were a prominent result of the market and regulatory environment, with reverse mergers remaining a fixture and stock-for-stock deals and take-private transactions led by privateequity sponsors entering the scene.
John Prothrow and his investor friends put capital, energy, and professionalism behind the business. The brand also receives many medical referrals from podiatrists and other foot specialists. Foot Solutions is not a medical provider, but it receives many medical referrals from podiatrists and other foot specialists.
Ongoing and renewed armed conflict and climate and energy risks had far-reaching impacts, not only affecting national security, global stability and public debate, but also dampening investor sentiment and generally quieting dealmaking in the aggregate. trillion) and an unprecedented stockpile of exit deals in the pipeline.
However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined privateequity sponsor buyers. trillion. [2]
In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. billion strategic combination of One Medical and Iora Health – used all stock. [9] time highs in 2021.
Behavioral Health, Infusion, and Staffing firms top the list in BRGs survey Many lower middle market privateequity groups have revisited their investment priorities as we enter 2025, making room for new opportunities across healthcare verticals. These drugs are also increasingly delivered via infusion, and investors are taking notice.
His journey from struggling student to real estate investor, then into SBA lending and franchise brokering, highlights the resilience and adaptability needed for success in business. Some are owned by privateequity firms, which can change the dynamics of the business, sometimes prioritizing investor returns over franchisee success.
In 2024, infusion therapy services reached the highest volume of deals to date, all of which were completed by privateequityinvestors. Privateequityinvestors see these new options as an attractive growth opportunity for an already thriving industry.
For example, there are multi-billion-dollar biotech hedge funds with 10%, 20%, or even 30% of their total capital in single companies : 3) Public / Private Crossover Finally, many biotech hedge funds also have divisions that invest in private startups, similar to life sciences venture capital firms and healthcare growth equity firms.
For example, a manufacturing business broker may highlight a companys supply chain resilience and production capacity, while a healthcare broker may focus on patient retention and compliance with medical regulations. Industry connections Access to pre-vetted investors, privateequity firms, and business operators seeking expansion.
Financial Buyers : Privateequity firms and investment groups interested in businesses with strong cash flow and growth potential. For example, in a healthcare M&A transaction, an advisor might vet a prospective buyer interested in acquiring a medical practice.
Consumer retail privateequity is so diverse that it almost seems like a paradox. Depending on the firm, a consumer retail privateequity deal might consist of: A leveraged buyout of a struggling offline retailer. On the Job Recruiting Should You Go Shopping for Consumer Retail PrivateEquity Jobs?
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content